



BioCopy Holding AG  
Industriestraße 15  
CH-8355 Aadorf  
Switzerland

[www.biocopy.ch](http://www.biocopy.ch)

## Press Release

### **Webinar: BioCopy presents its innovative COVID-19 mutant mapping platform for developing new vaccines**

On Thursday, April 15, 4:30 – 5:30 pm, CEST, BioCopy will showcase its biomolecule copier in collaboration with Sino Biological, a global leader in recombinant technology, at the Festival of Biologics Congress. The Festival of Biologics is the meeting place for the life science community to bridge the gap between academia and industry.

BioCops technology enables the first high-throughput synthesis of protein arrays directly from DNA templates. This protein mapping platform enables to generate components of existing pathogens such as Covid-19 or more importantly their potential future variations.

In cooperation with Sino Biological, BioCopy analyzed over 90 COVID-19 related protein mutants to monitor inherent weaknesses of the immune system post infection and vaccination against emerging escape mutants of Covid-19.

Dr. Pascal Brenneisen (former CEO Novartis Switzerland and Advisory Board BioCopy AG), Dr. Günther Proll (former CEO Biometrics, now BioCopy Senior Scientist) and Dr. Günter Roth (CEO and founder BioCopy) will introduce the BioCopy technology, and how it is applied to enable the development of diagnostics or therapeutics for existing and future Covid-19 mutations.

[Follow our webinar and register here.](#)

#### **About BioCopy:**

BioCopy is a young development company with holding headquarters in Aadorf (Switzerland) and a research unit in Emmendingen, Germany. Behind BioCopy is a multi-award winning team of more than 20 experts and specialists with a broad know-how (biology, physics, engineering and microsystems technology and economics). BioCopy's platform technology is protected by a broad patent portfolio with 13 granted patents and 2 pending patents, all having long terms of well over 10 years. BioCopy's CEO and main founder is Dr. Günter Roth, a biochemist and physicist. Günter Roth released co-publishings with CureVac 10 years ago.

The BioCopy team is complemented by renowned board members, including Prof. Dr. Alexander von Gabain (co-founder of Intercell AG, now Valneva SE), Rainer Boehm (ex-

interim CEO and Chief Commercial and Medical Affairs Officer Novartis Pharma) and Pascal Brenneisen (ex-CEO Novartis Switzerland).

**About Sino Biological:**

Sino Biological specializes in antibody development and recombinant protein production. All of Sino Biological's products are independently developed and produced. Sino Biological offers pharmaceutical companies and biotechnology firms a variety of recombinant production and assay services for pre-clinical research development work. Sino Biological is dedicated to virology and infectious disease research. Its ProVir™ collection is the world's largest viral antigen bank, carrying over 800 products from 350 strains of viruses. Sino Biological is the first company in the world to produce and supply the SARS-CoV-2 viral protein reagents. To support the development of immunodiagnostic assay, Sino Biological has developed a comprehensive collection of antigens and antibodies for SARS-CoV-2.

Sino Biological Europe GmbH is the official branch of Sino Biological in Europe, located in Eschborn (by Frankfurt) Germany with the local sales/service team and the protein inventory.

Contact International:

Manfred Claassens, Presse BioCopy; +49 162 264 44 61; [presse@biocopy.de](mailto:presse@biocopy.de)

Contact Switzerland:

Barbara Ryter, Presse BioCopy; +41 43 501 33 06; [presse@biocopy.ch](mailto:presse@biocopy.ch)